Tempest Therapeutics, Inc. (NASDAQ: TPST) announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd., under which Tempest has acquired an exclusive option to license Senlang’s CD7‑targeted lentiviral vector platform and a portfolio of in vivo CAR‑T candidates — a modality designed to generate CAR‑T and CAR‑NK cells directly inside the patient’s body, eliminating ex vivo manufacturing. Financial terms of the agreement were not disclosed.
Deal Snapshot
| Item | Detail |
|---|---|
| Deal Type | Exclusive option to license |
| Optionee | Tempest Therapeutics, Inc. (NASDAQ: TPST) |
| Licensor | Hebei Senlang Biotechnology Co., Ltd. |
| Assets Covered | CD7‑targeted lentiviral vector platform + portfolio of in vivo CAR‑T candidates |
| Lead Program | Bispecific BCMA/GPRC5D‑targeting in vivo CAR‑T |
| Clinical Stage | Phase I dose‑escalation study – relapsed/refractory multiple myeloma |
| Financial Terms | Not disclosed |
| Announcement Date | 17 Sep 2026 |
Platform Profile & Mechanism of Action
- Delivery Modality: Senlang’s platform utilizes a targeted lentiviral vector engineered to home to endogenous CD7‑positive T cells and natural killer (NK) cells, delivering CAR transgenes directly to those cells in vivo.
- Mechanism: Transduced T and NK cells express the chimeric antigen receptor inside the patient’s body, generating CAR‑T and CAR‑NK effectors without external cell processing.
- Manufacturing Advantage: The approach aims to eliminate the need for individualized cell collection (leukapheresis) and ex vivo manufacturing associated with traditional autologous CAR‑T therapies — the principal drivers of cost, vein‑to‑vein time, and patient attrition in the field.
- CD7 Rationale: CD7 is broadly expressed on T and NK cells, enabling the vector to target the effector populations required for CAR generation; dual engagement of T cells and NK cells potentially broadens the anti‑tumor effector repertoire.
Clinical Evidence – Phase I Dose‑Escalation Study
- Lead Candidate: Bispecific BCMA/GPRC5D‑targeting in vivo CAR‑T — both are validated multiple myeloma antigens currently pursued by commercial CAR‑T and bispecific antibody therapies.
- Population: Patients with relapsed/refractory multiple myeloma (RRMM).
- Design: Phase I dose‑escalation study, focused on safety and dose finding.
- Data: Interim results, cohort sizes, and enrollment status were not disclosed.
Market Impact & Outlook
- In Vivo CAR‑T Frontier: Next‑generation in vivo CAR‑T is among the most closely watched areas in cell therapy, promising an “off‑the‑shelf” experience for a modality historically constrained by bespoke, per‑patient manufacturing.
- Option Structure De‑risks Tempest: During the option period, Tempest and Senlang will continue to evaluate Phase I results and Senlang’s broader pipeline before Tempest decides whether to exercise its option and enter into a definitive license agreement — a milestone‑gated structure that limits upfront capital commitment.
- Myeloma Landscape: RRMM remains a high‑unmet‑need indication with sequential relapses; a bispecific BCMA/GPRC5D in vivo CAR‑T, if validated, could offer a manufacturing‑light alternative to existing autologous products.
- Next Catalysts: Phase I dose‑escalation readouts, pipeline evaluations, and Tempest’s option‑exercise decision — timing and criteria not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the exclusive option agreement, the potential exercise of the option, and the clinical development and commercialization of Senlang’s in vivo CAR‑T platform and candidates. An option agreement does not guarantee that a license will be executed. Actual results may differ materially due to risks including clinical trial outcomes, manufacturing scalability, regulatory review, and competitive dynamics.-Fineline Info & Tech
